Heart Failure

  • 8212- Preserved: Phase 2, Multicentre, randomised, double-blind, placebo-controlled safety and efficacy study of CDR132L on reverse cardiac remodelling in participants with heart failure with preserved ejection fraction and left ventricular hypertrophy. Sumanth Prabhu, M.D. Novo Nordisk A/S.
    CURRENTLY ENROLLING
    view on clinicaltrials.gov
  • Amber: A multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CK4021586 in adults with symptomatic heart failure with preserved ejection fraction. Justin Hartupee, M.D. Cytokinetics, Inc.
    CURRENTLY ENROLLING
    view on clinicaltrials.gov
  • ATHENA: Effects of ziltivekimab versus placebo on heart failure symptoms and physical function in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation. Justin Vader, MD. Novo Nordisk.
    CLOSED TO ENROLLMENT
    view on clinicaltrials.gov
  • CLARITY-FA: Characteristics and clinical course of disease in participants with cardiomyopathy associated with Friedreich Ataxia. Arun Varadhachary, M.D. Lexeo Therapeutics.
    CURRENTLY ENROLLING
  • COMET: A multi-center, double-blind, randomized placebo-controlled trial to assess efficacy and safety of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction. Justin Vader, MD. Cytokinetics, Inc.
    CURRENTLY ENROLLING
    view on clinicaltrials.gov
  • CORCINCH:  Randomized clinical evaluation of the AccuCinch Ventricular Restoration System in patients who present with symptomatic heart failure with reduced ejection fraction.  Justin Vader, MD. Ancora Heart.
    CURRENTLY ENROLLING
    view on clinicaltrials.gov
  • DCM Consortium:  Identification of the genetic causes of dilated cardiomyopathy and related conditions. Gregory Ewald, MD. Ohio State University.
    view on clinicaltrials.gov
    view on clinicaltrials.gov
  • KINSHIP-DCM: A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy. Gregory Ewald, M.D. Kardigan, Inc.
    CURRENTLY ENROLLING
    view on clinicaltrials.gov
  • MUSIC-HF:  Phase I/II trial of the safety and efficacy of SRD-001 in subjects with heart failure with reduced ejection fraction. Gregory Ewald, MD. Sardocor Corp.
    CURRENTLY ENROLLING
    view on clinicaltrials.gov
  • REBIRTH:  Randomized evaluation of bromocriptine in myocardial recovery therapy for peripartum cardiomyopathy. Gregory Ewald, MD. University of Pittsburgh.
    CURRENTLY ENROLLING
    view on clinicaltrials.gov
  • REHAB-pEF  Physical Rehabilitation for older patients with acute heart failure with preserved ejection fraction. Justin Vader, MD. National Institute of Aging.
    CURRENTLY ENROLLING
    view on clinicaltrials.gov
  • RESONANCE: Registry of the natural history of recurrent pericarditis in pediatric and adult patients. Amanda Verma, MD. Kiniksa Pharmaceuticals.
    view on clinicaltrials.gov
  • SALUBRIS:  A study to assess the safety and tolerability of JK07 in subjects with heart failure with preserved ejection fraction. Nancy Sweitzer, MD. Salubris Biotherapeutics, Inc.
    CURRENTLY ENROLLING
    view on clinicaltrials.gov
  • SHORE:  Surveillance Heartcare (allomap and allosure) outcomes registry. Gregory Ewald, MD. CareDx.
    view on clinicaltrials.gov
  • TCBR:  Translational cardiovascular biobank and repository. Gregory Ewald, MD.  Washington University.